Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04759651
Other study ID # 2020.482.IRB1.172
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date June 30, 2023

Study information

Verified date April 2022
Source Koç University
Contact Suat Erus, MD
Phone +905325506947
Email serus@ku.edu.tr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main aim of this study is to prospectively evaluate the occurrence of sleep disorders in patients undergoing thoracic surgery due to the preliminary diagnosis of lung cancer. Secondary aims include anxiety, depressive mood and functional outcomes before and 3 months after the intervention.


Description:

Cancer surgery is one of the traumas that affect human life, starting from diagnostic procedures, along with the recovery process. Although 5-year survival in lung cancer has increased to 60%, there is a general prejudice that lung cancer has a poor prognosis. A preliminary diagnosis of a such condition has consequently a negative effect on the mood and sleep patterns of the patients, starting already from the beginning of the diagnostic procedures. In our study, we want to evaluate the occurrence of sleep disorders, anxiety, depressive mood and functional outcomes before and 3 months after the surgical intervention. This would also help us to better identify the patients in need for professional support for sleep disorders as well as psychiatric conditions, and thus, a better management of patients with lung cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date June 30, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who will undergo lung resection with a pre-diagnosis of lung cancer - Being literate or having the physical strength to answer questions. Exclusion Criteria: - The patient has a chronic disease such as dementia or treatment-resistant schizophrenia in which reality assessment is impaired. - Patients who have received chemotherapy and / or radiotherapy due to their previous disease.

Study Design


Intervention

Other:
Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)
Sleep related quality of life questionnaire.
Epworth Sleepiness Scale (ESS)
Subjective level of daytime sleepiness.
Berlin Questionnaire
Evaluation of high-risk for Obstructive Sleep Apnea.
Stop-Bang Questionnaire
Evaluation of high-risk Obstructive Sleep Apnea.
Insomnia Questionnaire
Subjective evaluation of insomnia.
Restless Leg Syndrome Questionnaire
Subjective evaluation of Restless Leg Syndrome.
Zung Self-rating Depression Scale (SDS)
Subjective test for evaluation of depressive mood.
Beck Anxiety Inventory
Subjective test for evaluation of anxiety.

Locations

Country Name City State
Turkey Koç University Hospital Istanbul

Sponsors (6)

Lead Sponsor Collaborator
Koç University Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Marmara University, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, Trakya University School of Medicine, Yedikule Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Functional Outcome of Sleep Questionnaire scores Sleep related quality of life. Score range: 5-20 points, with higher scores indicating better functional status. 3 months
Primary Change from baseline in Epworth Sleepiness Scale scores Excessive daytime sleepiness. Score range: 0-24 points, with higher scores indicating greater daytime sleepiness. Scores =11 are generally considered to be abnormal, or positive for excessive daytime sleepiness. 3 months
Primary Change from baseline in Berlin Questionnaire scores High-risk Obstructive Sleep Apnea. Patients can be classified into High Risk or Low Risk based on their responses to the individual items and their overall scores in the symptom categories. 3 months
Primary Change from baseline in STOP-BANG questionnaire scores High-risk Obstructive Sleep Apnea. Score range: 0-8 points, patients with a STOP-Bang score of 0 to 2 can be classified as low risk for moderate to severe OSA whereas those with a score of 5 to 8 can be classified as high risk for moderate to severe OSA.
The STOP-BANG is an assessment tool used to help diagnose Obstructive Sleep Apnea
3 months
Primary Change from baseline in Insomnia questionnaire scores Insomnia questionnaire. Score range: 0-28 points, with higher scores indicating greater insomnia severity. 3 months
Primary Change from baseline in Restless Legs Syndrome questionnaire scores Restless Leg Syndrome questionnaire. Score range: 0-4 points, with higher scores indicating more severe symptoms 3 months
Secondary Change from baseline in Zung Self-rating Depression Scale scores Zung Self-rating Depression Scale. Score range: 0-80 points, most people with depression score between 50 and 69, while a score of 70 and above indicates severe depression. 3 months
Secondary Change from baseline in Beck Anxiety Inventory scores Self-rating anxiety scale. Score range: 0-63 points, a total score of 0 - 7 is interpreted as a "Minimal" level of anxiety; 8 - 15 as "Mild"; 16 - 25 as "Moderate", and; 26 - 63 as "Severe". 3 months
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk